Siamak Moradian

Siamak Moradian

Auto-generated profile, based on publicly available information

Siamak Moradian

Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Ophthalmology
Verified
Journal Article
Closed access
MSMasoud Soheilian
Masoud Soheilian
ARAlireza Ramezani
Alireza Ramezani
AOArash Obudi
Arash Obudi
BBBijan Bijanzadeh
Bijan Bijanzadeh
MSMasoud Salehipour
Masoud Salehipour
GPGholam A. Peyman
Gholam A. Peyman

1 August 2005 in Ophthalmology
Verified
Journal Article
Closed access
HAHamid Ahmadieh
Hamid Ahmadieh
SMSiamak Moradian
Siamak Moradian
HFHooshang Faghihi
Hooshang Faghihi
MPMohammad M. Parvaresh
Mohammad M. Parvaresh
HGHeshmatollah Ghanbari
Heshmatollah Ghanbari
BGBanafsheh Golestan
Banafsheh Golestan

12 August 2008 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
SMSiamak Moradian
Siamak Moradian
HAHamid Ahmadieh
Hamid Ahmadieh
MMMohsen Malihi
Mohsen Malihi
MSMasoud Soheilian
Masoud Soheilian
MDMohammad Hossein Dehghan
Mohammad Hossein Dehghan
MAMohsen Azarmina
Mohsen Azarmina

1 November 2007 in Retina
Verified
Journal Article
Closed access
MSMasoud Soheilian
Masoud Soheilian
ARAlireza Ramezani
Alireza Ramezani
BBBijan Bijanzadeh
Bijan Bijanzadeh
MYMehdi Yaseri
Mehdi Yaseri
HAHamid Ahmadieh
Hamid Ahmadieh
GPGholam A. Peyman
Gholam A. Peyman
To report the efficacy of a single intravitreal bevacizumab injection alone or in combination with intravitreal triamcinolone acetonide versus macular laser photocoagulation (MPC) as primary treatment of diabetic macular edema (DME). In this randomized, three-arm clinical trial, 103 eyes of 97 patients with clinically significant DME and no previous treatment were enrolled. The eyes were randomly assigned to one of three study arms: the intravitreal bevacizumab (IVB) group, patients who received 1.25 mg of intravitreal bevacizumab (37 eyes); the IVB/IVT group, patients who received 1.25 mg of intravitreal bevacizumab and 2 mg of intravitreal triamcinolone (33 eyes); and the MPC group, patients who underwent focal or modified grid laser (33 eyes). Primary outcome measure was change in visual acuity. Visual acuity changes +/- SD at 12 weeks were -0.22 +/- 0.23, -0.13 +/- 0.31, and + 0.08 +/- 0.31 logarithm of the minimal angle of resolution in the IVB, IVB/IVT, and MPC groups, respectively. The marginal regression model based on generalized estimating equation analysis demonstrated that the visual acuity changes in the groups were statistically significant at both 6 weeks (P < 0.0001) and 12 weeks (P = 0.024). The significant treatment effect was demonstrated at both 6 weeks and 12 weeks in the IVB group and only at 6 weeks in the IVB/IVT group. Significant central macular thickness (CMT) reduction was observed in eyes in the IVB and IVB/IVT groups only up to 6 weeks; however, CMT changes were not significant in the groups. Up to 12 weeks, intravitreal bevacizumab treatment of patients with DME yielded better visual outcome than laser photocoagulation, although it was not associated with a significant decrease in CMT. No further beneficial effect of intravitreal triamcinolone could be demonstrated. Further clinical trials with longer follow-up are required to evaluate the long-term visual outcomes and complication profiles after primary treatment with such medications.

1 April 2009 in Retina
Verified
Journal Article
Closed access
MSMasoud Soheilian
Masoud Soheilian
ARAlireza Ramezani
Alireza Ramezani
MMMohsen Malihi
Mohsen Malihi
MYMehdi Yaseri
Mehdi Yaseri
HAHamid Ahmadieh
Hamid Ahmadieh
GPGholam A. Peyman
Gholam A. Peyman
Purpose: To evaluate the clinical features and functional and anatomical outcomes after surgical intervention in pediatric rhegmatogenous retinal detachment. Methods: In this retrospective case series, pediatric patients with rhegmatogenous retinal detachment who had surgical intervention were included. Cases were categorized into five main etiology groups: congenital or developmental (48 eyes); trauma (54 eyes); myopia alone (12 eyes); previous intraocular surgery (10 eyes); and miscellaneous (3 eyes). Patients‘ demographic, clinical, and surgical outcomes, as well as fellow eye findings were evaluated. Results: One hundred twenty-seven eyes of 108 patients (mean age: 12.1 ± 4.1 year, 80.6% male) were included. Scleral buckling was the initial procedure in 31% of eyes and vitrectomy in 63%. Mean follow-up was 34 ± 21 months (median 33 months). Retinal reattachment at last follow-up was achieved in 74.9% of eyes. Visual acuity was ≥20/200 in 14% of eyes preoperatively and in 47.9% of eyes at final follow-up (P = 0.001). Retinal pathologies (mostly lattice degeneration) were noted in 82.2% of fellow eyes. Conclusion: Trauma and congenital-developmental anomalies were the leading etiologies in pediatric rhegmatogenous retinal detachment in this review. Despite the complexity of rhegmatogenous retinal detachment and presence of vision-threatening anomalies, anatomic and functional outcomes were acceptable. Regular ophthalmoscopy of the sound eye is recommended for children at risk.

1 June 2006 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
ARAlireza Ramezani
Alireza Ramezani
MEMorteza Entezari
Morteza Entezari
SMSiamak Moradian
Siamak Moradian
HTHoma Tabatabaei
Homa Tabatabaei
SKShohreh Kadkhodaei
Shohreh Kadkhodaei